Contraceptive Containing a Folate Approved

Designed to help prevent certain birth defects
By Scott Roberts
HealthDay Reporter

MONDAY, Sept. 27 (HealthDay News) -- Beyaz, a combination estrogen/progestin contraceptive that also contains a folate, has been approved by the U.S. Food and Drug Administration.

The folate, levomefolate calcium, is a B-vitamin that's among a class of vitamins recommended for women of childbearing age. Lack of dietary folate has been associated with neural tube birth defects, which involve deformities of the fetal brain or spinal cord. The newly approved drug is designed to boost folate levels and help prevent this type of defect among mothers who conceive shortly after discontinuing the drug.

Beyaz was studied in a multi-center U.S. trial involving 379 women aged 18 to 40. The most frequently reported side effects included uterine bleeding, nausea, breast tenderness and headache. Other serious side effects included blood clots and liver disease.

Women 35 or older should not use Beyaz, which could increase their risk of "serious cardiovascular events," the agency said.

Beyaz is based on the already approved contraceptive YAZ, which includes the same amounts of estrogen and progestin, the FDA said.

The newly approved drug is produced by Bayer HealthCare Pharmaceuticals.

More information

The FDA has more about this approval.

Copyright © 2010 HealthDay. All rights reserved.

Powered by

Featured Jobs



Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member